1
|
Teofili L, Valentini CG, Aceto P, Bartolo M, Sollazzi L, Agnes S, Gaspari R, Avolio AW. High intraoperative blood product requirements in liver transplantation: risk factors and impact on the outcome. Eur Rev Med Pharmacol Sci 2022; 26:64-75. [PMID: 35049021 DOI: 10.26355/eurrev_202201_27749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
OBJECTIVE Liver transplantation (LT) is associated with a significant bleeding and the high transfusion requirements (HTR) negatively affect the outcome of LT patients. Our primary aim was to identify potential predictors of intraoperative transfusion requirements. Secondarily, we investigated, the effect of transfusion requirements on different clinical outcomes, including short-term morbidity and mortality. PATIENTS AND METHODS Data collected in 219 adult LT from a deceased donor, grouped according to HTR (defined as the need of 5 or more red blood cell units), were compared. RESULTS We found that previous portal vein thromboses (p=0.0156), hemoglobin (Hb) (p<0.0001), International Normalized Ratio (INR) (p=0.0010) at transplant and veno-venous by-pass (p=0.0048) independently predicted HTR. HTR was always associated with poorer outcomes, including higher simplified acute physiology II score at Intensive Care Unit admission (p=0.0005), higher rates of pulmonary infections (p=0.0015) and early rejection (p=0.0176), longer requirement of mechanical ventilation, (p<0.0001), more frequent need for hemodialysis after transplantation (p=0.0036), overall survival (p=0.0010) and rate of day-90 survival (p=0.0016). CONCLUSIONS This study identified specific risk factors for HTR and confirmed the negative impact exerted by HTR on clinical outcomes, including recipient survival. Prospective investigations are worth to assess whether correcting pre-transplant Hb and INR levels may effectively reduce blood product need and improve prognosis.
Collapse
Affiliation(s)
- L Teofili
- Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Leone G, Stefano VD, Ferrelli R, Teofili L, Tengborn L, Vahtera E, Bizzi B. Antithrombin III Molecular Variants with Defective Binding to Heparin or to Serine Proteases: Evidence of Two Different Abnormal Patterns Identified by Crossed Immunoelectrofocusing. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1647624] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryMolecular heterogeneity of antithrombin III (AT III) was investigated by a technique of crossed immunoelectrofocusing (CIEF) in plasma samples of patients from 16 families with AT III congenital defect, including 8 AT III molecular variants. The AT III CIEF pattern was normal in all the patients with AT III quantitative deficiency, showing a balanced decrease of all the peaks. Out of the 8 AT III variants investigated, 6 had an abnormal pattern: the three variants with defective binding to heparin (AT III Roma, AT III Barcelona, AT III Malmö) shared a similar abnormal pattern; three variants with defective binding to serine proteases (AT III Pescara, AT III Milano, AT III Tampere) had a common abnormal pattern clearly different from the first one, whereas the other two variants deficient in the inactivation of the serine proteases (AT III Chicago, AT III Milano 2) showed a normal pattern. The first type of pathological pattern (type Roma) was characterized by the presence of an abnormal peak overlapping the normal isoforms present at pH 4.8-4.6 and by an additional peak at pH 4.5. The second type of pattern (type Pescara) showed an additional peak at pH 4.5 and an abnormal quantitative distribution of the isoantithrombins all throughout the pH range (5.2-4.6). In order to separate the abnormal AT III fraction from the normal one, plasma of a patient with Roma defect and serum of a patient with Pescara defect were passed throughout an heparin-ultrogel column. The CIEF of the different AT III Roma and AT III Pescara fractions obtained by affinity chromatography confirmed that the abnormalities found in the corresponding patterns of the native samples were related to the pathological isoantithrombins only. It was concluded that the CIEF can be an useful tool to characterize abnormal antithrombins and can reveal close affinities among AT III molecular variants belonging to different subgroups according to the conventional tests.
Collapse
Affiliation(s)
- G Leone
- The Istituto di Semeiotica Medica, Università Cattolica, Roma, Italy
| | - V De Stefano
- The Istituto di Semeiotica Medica, Università Cattolica, Roma, Italy
| | - R Ferrelli
- The Istituto di Semeiotica Medica, Università Cattolica, Roma, Italy
| | - L Teofili
- The Istituto di Semeiotica Medica, Università Cattolica, Roma, Italy
| | - L Tengborn
- The Department for Coagulation Disorders, University of Lund, Malmö, Sweden
| | - E Vahtera
- The Finnish Red Cross Blood Transfusion Service, Helsinki, Finland
| | - B Bizzi
- The Istituto di Semeiotica Medica, Università Cattolica, Roma, Italy
| |
Collapse
|
3
|
Paciaroni K, Chiusolo P, Casorelli I, Rossi E, Teofili L, Di Mario A, Leone G, De Stefano V. Cerebral Vein Thrombosis not Related to Use of Oral Contraceptives in a 7-year-old Child Carrier of the Prothrombin 20210A Allele. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1614614] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
4
|
Zaccardi F, Rocca B, Rizzi A, Ciminello A, Teofili L, Ghirlanda G, De Stefano V, Pitocco D. Platelet indices and glucose control in type 1 and type 2 diabetes mellitus: A case-control study. Nutr Metab Cardiovasc Dis 2017; 27:902-909. [PMID: 28838851 DOI: 10.1016/j.numecd.2017.06.016] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/22/2017] [Revised: 05/23/2017] [Accepted: 06/27/2017] [Indexed: 01/13/2023]
Abstract
BACKGROUND AND AIMS The relationship between platelet indices and glucose control may differ in type 1 (T1DM) and type 2 (T2DM) diabetes. We aimed to investigate differences in mean platelet volume (MPV), platelet count, and platelet mass between patients with T1DM, T2DM, and healthy controls and to explore associations between these platelet indices and glucose control. METHODS AND RESULTS A total of 691 T1DM and 459 T2DM patients and 943 control subjects (blood donors) were included. HbA1c was measured in all subjects with diabetes and 36 T1DM patients further underwent 24 h-continuous glucose monitoring to estimate short-term glucose control (glucose mean and standard deviation). Adjusting for age and sex, platelet count was higher and MPV lower in both T1DM and T2DM patients vs control subjects, while platelet mass (MPV × platelet count) resulted higher only in T2DM. Upon further adjustment for HbA1c, differences in platelet count and mass were respectively 19.5 × 109/L (95%CI: 9.8-29.3; p < 0.001) and 101 fL/nL (12-191; p = 0.027) comparing T2DM vs T1DM patients. MPV and platelet count were significantly and differently related in T2DM patients vs both T1DM and control subjects; this difference was maintained also accounting for HbA1c, age, and sex. Platelet mass and the volume-count relationship were significantly related to HbA1c only in T1DM patients. No associations were found between platelet indices and short-term glucose control. CONCLUSION By accounting for confounders and glucose control, our data evidenced higher platelet mass and different volume-count kinetics in subjects with T2DM vs T1DM. Long-term glucose control seemed to influence platelet mass and the volume-count relationship only in T1DM subjects. These findings suggest different mechanisms behind platelet formation in T1DM and T2DM patients with long-term glycaemic control being more relevant in T1DM than T2DM.
Collapse
Affiliation(s)
- F Zaccardi
- Diabetes Research Centre, University of Leicester, Leicester, UK; Diabetes Care Unit, Catholic University School of Medicine, Rome, Italy.
| | - B Rocca
- Institute of Pharmacology, Catholic University School of Medicine, Rome, Italy
| | - A Rizzi
- Diabetes Care Unit, Catholic University School of Medicine, Rome, Italy
| | - A Ciminello
- Institute of Haematology, Catholic University School of Medicine, Rome, Italy
| | - L Teofili
- Institute of Haematology, Catholic University School of Medicine, Rome, Italy
| | - G Ghirlanda
- Diabetes Care Unit, Catholic University School of Medicine, Rome, Italy
| | - V De Stefano
- Institute of Haematology, Catholic University School of Medicine, Rome, Italy
| | - D Pitocco
- Diabetes Care Unit, Catholic University School of Medicine, Rome, Italy
| |
Collapse
|
5
|
Martini M, Capodimonti S, Iachininoto MG, Cocomazzi A, Nuzzolo ER, Voso MT, Teofili L, Larocca LM. An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome. Blood Cancer J 2015; 5:e370. [PMID: 26617063 PMCID: PMC4670949 DOI: 10.1038/bcj.2015.97] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Affiliation(s)
- M Martini
- Istituto di Anatomia Patologica, Università Cattolica del Sacro Cuore, Rome, Italy
| | - S Capodimonti
- Istituto di Ematologia, Università Cattolica del Sacro Cuore, Rome, Italy
| | - M G Iachininoto
- Istituto di Ematologia, Università Cattolica del Sacro Cuore, Rome, Italy
| | - A Cocomazzi
- Istituto di Anatomia Patologica, Università Cattolica del Sacro Cuore, Rome, Italy
| | - E R Nuzzolo
- Istituto di Ematologia, Università Cattolica del Sacro Cuore, Rome, Italy
| | - M T Voso
- Department of Biomedicine and Prevention, Università di Roma Tor Vergata, Roma, Italy
| | - L Teofili
- Istituto di Ematologia, Università Cattolica del Sacro Cuore, Rome, Italy
| | - L M Larocca
- Istituto di Anatomia Patologica, Università Cattolica del Sacro Cuore, Rome, Italy
| |
Collapse
|
6
|
Valentini CG, Nuzzolo ER, Orlando N, Metafuni E, Bianchi M, Chiusolo P, Zini G, Teofili L. Cytokine profile of autologous platelet-derived eye drops in patients with ocular chronic graft-versus-host disease. Vox Sang 2015; 110:189-92. [PMID: 26383050 DOI: 10.1111/vox.12325] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2015] [Revised: 07/23/2015] [Accepted: 07/28/2015] [Indexed: 12/14/2022]
Abstract
Ocular chronic GVHD is efficaciously treated with autologous platelet-derived eye drops. We investigated the cytokine content of eye drops produced using a non-gelified lysate obtained from autologous platelet-rich plasma in six patients with ocular GVHD. In both the responding (n = 4) and the resistant (n = 2) patients, the eye drops were significantly enriched with various growth factors, in amounts proportional with the platelet counts. In contrast, chemokine ligand and interleukin levels were similar to those of plasma. The non-responding patients showed the highest levels of chemokine (C-X-C motif) ligand (CXCL)10. These findings provide possible explanations for beneficial or detrimental effects of eye drops.
Collapse
Affiliation(s)
- C G Valentini
- Medicine Transfusion Department, Institute of Hematology, Catholic University, Rome, Italy
| | - E R Nuzzolo
- Medicine Transfusion Department, Institute of Hematology, Catholic University, Rome, Italy
| | - N Orlando
- Medicine Transfusion Department, Institute of Hematology, Catholic University, Rome, Italy
| | - E Metafuni
- Hematology Department, Institute of Hematology, Catholic University, Rome, Italy
| | - M Bianchi
- Medicine Transfusion Department, Institute of Hematology, Catholic University, Rome, Italy
| | - P Chiusolo
- Hematology Department, Institute of Hematology, Catholic University, Rome, Italy
| | - G Zini
- Medicine Transfusion Department, Institute of Hematology, Catholic University, Rome, Italy
| | - L Teofili
- Medicine Transfusion Department, Institute of Hematology, Catholic University, Rome, Italy
| |
Collapse
|
7
|
Teofili L, Nuzzolo E, Martini M, Capodimonti S, Cocomazzi A, Iachininoto M, Voso M, Larocca L. P-236 Endothelial progenitor cells in MDS patients show specific genetic signatures and abnormal cytokine production which could contribute to myelodysplastic hematopoiesis. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70283-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Cingolani A, Torti L, Pinnetti C, de Gaetano Donati K, Murri R, Tacconelli E, Larocca LM, Teofili L. Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastin in HIV-infected patients with Hodgkin lymphoma. J Int AIDS Soc 2010. [PMCID: PMC3113000 DOI: 10.1186/1758-2652-13-s4-p215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
9
|
Manfrida S, Chiesa S, Teofili L, Diletto B, Hohaus S, Fiorentino A, De Bari B, Frascino V, Aristei C, Balducci M. 44 High dose methotrexate followed by temozolomide plus concomitant radiation therapy in patients with newly diagnosed primary central nervous system Lymphoma: Preliminary results of a phase I dose escalation study. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70715-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
10
|
Chiesa S, De Santis M, Teofili L, Manfrida S, Vannata B, Frascino V, Fiorentino A, Calcagni L, Hohaus S, Balducci M. 115 poster: Prognostic Value of Pre-Radiotherapy FDG-PET in Advanced Hodgkin’S Disease Treated by Beacopp Chemotherapy Regimen. Radiother Oncol 2010. [DOI: 10.1016/s0167-8140(15)34534-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Teofili L, Foa R, Giona F, Larocca LM. Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients? Haematologica 2008; 93:169-72. [DOI: 10.3324/haematol.12002] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
12
|
Garzia M, Sora F, Teofili L, Di Mario A, Voso MT, Rumi C, La Rocca LM, Sica S, Zini G. Blastoid Mantle Cell Lymphoma Occurring in a Patient in Complete Remission of Chronic Myelogenous Leukemia. ACTA ACUST UNITED AC 2007; 13:30-3. [PMID: 17353181 DOI: 10.1532/lh96.06030] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The development of a de novo lymphoma in patients affected by chronic myelogenous leukemia (CML) is a rare event. The introduction of new molecular cytogenetic techniques, such as fluorescence in situ hybridization (FISH), allows a correct differential diagnosis between lymphoid blastic crisis and a blastoid variant of mantle cell lymphoma (MCL), which shows an aggressive behavior and some molecular characteristics detectable by cytogenetics and immunohistochemistry. We report a case of a blastoid variant of MCL that developed in a patient with CML who achieved complete cytogenetic and molecular response to imatinib mesylate treatment.
Collapse
Affiliation(s)
- M Garzia
- Dipartimento di Diagnostica Morfologica, Microbiologica, Molecolare e delle Malattie del Sangue, Catholic University of Sacred Heart, Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Teofili L, Martini M, Luongo M, Diverio D, Capelli G, Breccia M, Lo Coco F, Leone G, Larocca LM. Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. Leukemia 2003; 17:919-24. [PMID: 12750706 DOI: 10.1038/sj.leu.2402907] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
We evaluated the methylation status of p15 gene in a series of 65 patients with newly diagnosed acute promyelocytic leukemia (APL) receiving homogeneous treatment. Moreover, in 32 of them, the methylation status of p15 gene was correlated to the p15 m-RNA expression. In total, 31 patients had no p15 methylation (U group). An abnormal methylation pattern was found in 34 patients: in seven of these patients only methylated DNA was detected (M group), while in the remaining 27 patients (M/U group), both methylated and unmethylated DNA were amplified. Patients from M group showed a higher incidence of relapses and a lower disease-free survival (DSF) with respect to patients from U and M/U groups (29, 64 and 79% at 5 years for M, U/M and U patients, respectively, P=0.03), while p15 methylation had no impact on overall survival. The p15 expression was detectable in all patients with unmethylated DNA, in none of patients with fully methylated DNA and in 60% of patients with partially methylated DNA. The DFS estimate at 5 years for p15-negative patients was significantly lower than that of p15-positive patients (P=0.03). These data confirm that the presence of p15 methylation negatively influences the prognosis of APL, mainly when it represses the p15 gene transcription.
Collapse
MESH Headings
- Adult
- Bone Marrow/metabolism
- Bone Marrow/pathology
- Cell Cycle Proteins/genetics
- Cell Cycle Proteins/metabolism
- Cyclin-Dependent Kinase Inhibitor p15
- Cyclin-Dependent Kinase Inhibitor p16/genetics
- Cyclin-Dependent Kinase Inhibitor p16/metabolism
- DNA Methylation
- DNA Primers/chemistry
- DNA, Neoplasm/genetics
- Dinucleoside Phosphates/genetics
- Enzyme Inhibitors/metabolism
- Female
- Follow-Up Studies
- Gene Expression Regulation, Neoplastic
- Gene Silencing
- Genes, Tumor Suppressor
- Humans
- Immunoenzyme Techniques
- Leukemia, Promyelocytic, Acute/genetics
- Leukemia, Promyelocytic, Acute/pathology
- Leukemia, Promyelocytic, Acute/therapy
- Male
- Neoplasm Recurrence, Local/genetics
- Polymerase Chain Reaction
- Prognosis
- Promoter Regions, Genetic/genetics
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- RNA, Neoplasm/genetics
- Sulfites/metabolism
- Survival Rate
- Syndrome
- Treatment Outcome
- Tumor Suppressor Proteins
Collapse
Affiliation(s)
- L Teofili
- Department of Hematology, Catholic University Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Leone G, Sica S, Chiusolo P, Teofili L, De Stefano V. Blood cells diseases and thrombosis. Haematologica 2001; 86:1236-44. [PMID: 11726314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023] Open
Abstract
BACKGROUND AND OBJECTIVES In recent years knowledge about thrombophilia and the mechanisms underlying the pathogenesis of thrombosis has increased greatly. Nevertheless the role of leukocytes and red cells in thrombogenesis is not well established and is probably underestimated. EVIDENCE AND INFORMATION SOURCES The contribution of leukocytes and red cells to thrombogenesis has been reviewed. Moreover, the prevalence of thrombosis as a complication of hematologic diseases has been examined. The authors are involved in the investigation and management of acute and chronic hematologic diseases as well as in investigation of thrombophilia. Pub-Med was employed as a source of information. STATE OF THE ART Thrombosis is a major problem in myeloproliferative disorders such as polycythemia vera and essential thrombocythemia. A clonal involvement of megakaryocytopoiesis resulting in elevated levels of platelet-specific proteins, increased thromboxane generation, and expression of activation-dependent epitopes on the platelet surface is regarded as the main origin of thromboembolism; nevertheless, activation of leukocytes and the consequent release of elastase and alkaline phosphatase could play an important role, determining endothelial damage. Thrombosis is a relevant problem in some hemolytic anemias such as paroxysmal nocturnal hemoglobinuria and drepanocytosis. Thrombotic events in hemolytic anemias with membrane defects have been attributed, at least in part, to hypercoagulability related to the exposure of phosphatidylserine of red cell membrane activating plasma prothrombinase and supplying a procoagulant phospholipid anionic surface. A moderate but well-established risk for thrombosis occurs in acute promyelocytic leukemia and acute lymphoblastic leukemia; this risk could be increased by antiblastic drugs affecting the procoagulant activity of cells and the production of coagulation inhibitors from the liver. PERSPECTIVES Thrombotic complications during hematologic diseases other than thrombophilia due to plasma alteration could be decreased not only by anticoagulant and antiaggregating agents but also by drugs inhibiting activation of leukocytes and red cells and their interaction with platelets.
Collapse
Affiliation(s)
- G Leone
- Istituto di Ematologia, Università Cattolica, largo Gemelli 8, 00168 Rome, Italy.
| | | | | | | | | |
Collapse
|
15
|
Teofili L, Martini M, Di Mario A, Rutella S, Urbano R, Luongo M, Leone G, Larocca LM. Expression of p15(ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. Blood 2001; 98:495-7. [PMID: 11435325 DOI: 10.1182/blood.v98.2.495] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
In myelodysplastic syndrome (MDS), the expression of the cyclin-dependent kinase inhibitor p15(ink4B) (p15) is frequently decreased because of the aberrant methylation of the gene promoter; p15 is normally up-regulated during megakaryocytic differentiation. It was hypothesized that p15 methylation and deregulation of gene expression contribute to defective megakaryocytopoiesis in patients with MDS. Here it is shown that the increasing autocrine production of TGF-beta1 stimulates megakaryocytic differentiation in normal CD34(+) cells and that p15 mediates, at least in part, this effect. This TGF-beta1-dependent pathway is altered in MDS CD34(+) progenitors because of p15 methylation. The demethylating agent 2-deoxyAZAcytidin can restore the normal demethylated state of the p15 gene and increase its expression. Nevertheless, MDS CD34(+) cells only poorly differentiate to the megakaryocytic lineage. These findings suggest that p15 methylation occurs in a neoplastic clone with a profound defect of cell proliferation, survival, and differentiation that cannot be overcome by using a demethylating drug.
Collapse
Affiliation(s)
- L Teofili
- Institutes of Hematology and Pathology, Università Cattolica del Sacro Cuore, Rome, Italy
| | | | | | | | | | | | | | | |
Collapse
|
16
|
|
17
|
Teofili L, Larocca LM, Leone G. Expression of p15(INK4B) in hematopoietic progenitors. Haematologica 2001; 84:E01. [PMID: 11084659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023] Open
|
18
|
Teofili L, Di Febo AL, Pierconti F, Maggiano N, Bendandi M, Rutella S, Cingolani A, Di Renzo N, Musto P, Pileri S, Leone G, Larocca LM. Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood 2001; 97:1063-9. [PMID: 11159538 DOI: 10.1182/blood.v97.4.1063] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
The receptor for hepatocyte growth factor (HGF) is a transmembrane tyrosine kinase that is encoded by the proto-oncogene c-met. Recently, c-MET was detected in Reed-Sternberg (RS) cells from Epstein-Barr virus-positive (EBV(+)) Hodgkin disease (HD). The c-MET, EBER-1, and LMP-1 expression in 45 lymph node biopsies and 12 bone marrow biopsies obtained from patients with HD was analyzed. In addition, HGF levels in serum samples from 80 healthy individuals and 135 HD patients in different phases of disease. In all 45 lymph node and 12 bone marrow samples examined, RS cells expressed c-MET but not HGF(+). These results were independent of the EBV infection. Interestingly, several HGF(+) dendritic-reticulum cells were found scattered around c-MET(+) RS cells. The mean +/- SEM serum HGF levels in HD patients at diagnosis and at the time of relapse were 1403 +/- 91 (95% confidence interval [CI], 1221-1585) and 1497 +/- 242 pg/mL (95% CI, 977-2017), respectively. HGF values were significantly higher than those of healthy individuals (665 +/- 28 pg/mL; 95% CI, 600-721; and P <.001 for both groups of patients) and of HD patients in remission (616 +/- 49 pg/mL; 95% CI, 517-714; and P <.001 for both groups of patients). A significant correlation was found between serum HGF levels and B symptoms at diagnosis (P =.014). In conclusion, this study indicates that HGF and c-MET constitute an additional signaling pathway between RS cells and the reactive cellular background, thereby affecting adhesion, proliferation, and survival of RS cells. Furthermore, the serum concentration of HGF in HD patients may be a useful tool in monitoring the status of disease.
Collapse
Affiliation(s)
- L Teofili
- Institutes of Hematology, Infectious Diseases, and Pathology, Università Cattolica del Sacro Cuore, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Pagano L, Ratto C, Teofili L, Larocca LM. Isolated primary Hodgkin's disease of rectum. Haematologica 2000; 85:986-7. [PMID: 10980640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
Affiliation(s)
- L Pagano
- Istituto di Semeiotica Medica, Università Cattolica S. Cuore, Largo Francesco Vito 1, I-00168 Roma, Italy.
| | | | | | | |
Collapse
|
20
|
La Barbera EO, Chiusolo P, Laurenti L, Menichella G, Di Febo AL, Piccirillo N, Sorà E, Marra R, Teofili L, Leone G, Sica S. MiCMA: an alternative treatment for refractory or recurrent Hodgkin's disease. Ann Oncol 2000; 11:867-71. [PMID: 10997816 DOI: 10.1023/a:1008329127887] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND We determined the response rate to MiCMA (mitoxantrone, carboplatinum, methylprednisolone and aracytin) in a group of 29 patients with Hodgkin's disease (HD) and poor prognostic factors either resistant to first line or relapsing after conventional chemotherapy and subsequently evaluated the role of autologous stem-cell transplantation (ASCT) in these patients after MiCMA. PATIENTS AND METHODS The treatment was intended as a brief tumor debulking program before ASCT. Twenty-nine patients with primary refractory HD or relapsed HD were submitted to two courses of MiCMA (mitoxantrone 10 mg/m2 day 1; carboplatinum 100 mg/m2 days 1-4; aracytin 2 g/m2 day 5; methylprednisolone 500 mg/m2 days 1-5) and subsequently evaluated for response. Those with responding or stable disease, received one or two other courses of MiCMA followed by ASCT. RESULTS There were 10 complete responses (34% CR), 15 partial responses (52% PR) and 4 treatment failures with disease progression (14% PD). In total there were 25 evaluable responses out of 29 patients (86% CR + PR). Myelosuppression was the main toxicity of this treatment. At this time 20 patients (69%) are alive with a median follow-up of 26.5 months (7-100), 13 patients in CR (45%), 8 patients died, 7 of them from disease progression and one due to multi-organ failure, one patient is lost to follow-up. All but one of the patients who achieved CR after MiCMA are alive. Only the number of extranodal sites was found to predict a poor response to MiCMA. CONCLUSIONS A short pre-transplantation treatment with MiCMA is an effective tumor debulking approach in patients with refractory or relapsed HD.
Collapse
Affiliation(s)
- E O La Barbera
- Department of Hematology, Istituto di Semeiotica Medica, Universita' Cattolica Sacro Cuore Roma, Italia
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Mele L, Pagano L, Equitani F, Chiusolo P, Rossi E, Zini G, Teofili L, Leone G. Lymphoid blastic crisis in Philadelphia chromosome-positive chronic granulocytic leukemia following high-grade non-Hodgkin's lymphoma A case report and review of literature. Haematologica 2000; 85:544-8. [PMID: 10800174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023] Open
Abstract
In this paper we describe a case of a 65-year old man with a lymphoid blastic crisis of a chronic granulocytic leukemia occurring seven years after a palatine tonsillar non-Hodgkin's lymphoma treated with chemotherapy and radiation therapy. Bone marrow cytogenetic study demonstrated the presence of the typical t(9;22)(q34;q11) and the molecular biology study showed the p210 rearrangement (b2a2). The patient died within a few months, unresponsive to any treatment. This is the first case, described in literature, of a secondary chronic granulocytic leukemia onset with a lymphoid blastic crisis. The authors report the case and a literature review.
Collapse
Affiliation(s)
- L Mele
- Istituto di Semeiotica Medica, Università Cattolica del Sacro Cuore, largo Francesco Vito 1, 00168 Rome, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Teofili L, Morosetti R, Martini M, Urbano R, Putzulu R, Rutella S, Pierelli L, Leone G, Larocca LM. Expression of cyclin-dependent kinase inhibitor p15(INK4B) during normal and leukemic myeloid differentiation. Exp Hematol 2000; 28:519-26. [PMID: 10812241 DOI: 10.1016/s0301-472x(00)00139-9] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE Expression of the cyclin-dependent kinase inhibitor p15(INK4B) frequently is altered in myeloid malignancies. We previously demonstrated that p15(INK4B) is expressed in normal myeloid cells. The aim of this study was to investigate whether p15(INK4B) expression is restricted to the granulomonocytic lineage and to evaluate its modulation during normal and leukemic myeloid differentiation. MATERIALS AND METHODS Normal CD34(+) cells were cultured in serum-free media to obtain granulomonocytic, erythroid, or megakaryocytic unilineage differentiation. NB4 promyelocytic cell line and fresh leukemic blasts from seven patients with acute promyelocytic leukemia were cultured with all-trans retinoic acid. At different times of culture, cell samples were collected to evaluate p15(INK4B) by semiquantitative reverse transcriptase polymerase chain reaction. RESULTS p15(INK4B) mRNA was found during granulomonocytic and megakaryocytic, but not erythroid, differentiation. In the granulomonocytic lineage, p15(INK4B) was detectable when the majority of cells were at the promyelocytic stage and increased progressively in more mature elements. In the megakaryocytic lineage, p15(INK4B) was expressed in the early phase of differentiation, before megakaryoblasts had appeared, and was mantained throughout the time of culture. NB4 cell line and five of seven leukemic samples displayed undetectable or very low level of p15(INK4B) that rapidly increased during retinoic acid-induced differentiation. Two leukemic samples (both collected from two patients developing all-trans retinoic acid syndrome) showed high basal levels of p15(INK4B), which was not modified by retinoic acid treatment. CONCLUSIONS p15(INK4B) upregulation occurs specifically during normal granulomonocytic and megakaryocytic commitment. In acute promyelocytic leukemic blasts, p15(INK4B), which is detectable at a very low level, is promptly increased by retinoic acid. In contrast, two acute promyelocytic leukemia samples obtained from patients who developed all-trans retinoic acid syndrome showed high basal levels of p15(INK4B) that did not increase further during all-trans retinoic acid-induced differentiation.
Collapse
Affiliation(s)
- L Teofili
- Departments of Hematology, Catholic University, Rome, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Aglietta M, Montemurro F, Fagioli F, Volta C, Botto B, Cantonetti M, Racanelli V, Teofili L, Ferrara R, Amadori S, Castoldi GL, Dammacco F, Levis A. Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease. Cancer 2000; 88:454-60. [PMID: 10640980 DOI: 10.1002/(sici)1097-0142(20000115)88:2<454::aid-cncr28>3.0.co;2-q] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND Granulocyte-macrophage-colony stimulating factor (GM-CSF) administration stimulates the proliferation of hemopoietic progenitors. Shortly (48-96 hours) after its discontinuation, feedback phenomena occur and the progenitor proliferation rate drops below baseline levels. As the quiescence of hyperplastic bone marrow suggests that hemopoietic cells may be refractory to the toxic effects of cytostatic drugs, the decision was made to test the hypothesis that GM-CSF given before chemotherapy may be myeloprotective. METHODS Fifty-six patients with newly diagnosed Stage II-IV Hodgkin disease, ages 18-77 years, were randomized to receive GM-CSF (5 microg/kg subcutaneously) or placebo from Day 7 to Day 4 before each chemotherapy administration (6 cycles of a hybrid of mechlorethamine, vincristine, procarbazine, and prednisone with doxorubicin, bleomycin, vinblastine, and dacarbazine). The treatment was considered a success if the delivery rate of chemotherapy was >90% after 3 cycles and >80% after 6 cycles. RESULTS Thirty patients received GM-CSF and 26 placebo. The dose intensity (85.2% vs. 79.6%) and the overall success in terms of delivery rate (56.7% vs. 50%) were higher in the GM-CSF group, although these differences were not statistically significant. The neutrophil nadirs were higher in the GM-CSF group during the first three cycles and subsequently similar in both groups. CONCLUSIONS No significant differences in terms of myelotoxicity or drug delivery were observed between the two treatment arms. Although the myeloprotective effect of the prechemotherapy administration of GM-CSF seems to be minimal, the data indicate a safe timing between GM-CSF discontinuation and further chemotherapy. Because cumulative myelotoxicity has been observed with other growth factors, given in the interval between the chemotherapy cycles, this may be relevant to the planning of rapid cycling.
Collapse
Affiliation(s)
- M Aglietta
- Divisione Universitaria di Oncologia ed Ematologia, Ospedale Mauriziano Umberto I-Istituto per la Ricerca e la Cura del Cancro (I. R.C.C.), Torino, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
De Stefano V, Paciaroni K, Chiusolo P, Casorelli I, Rossi E, Teofili L, Di Mario A, Leone G. Cerebral vein thrombosis not related to use of oral contraceptives in a 7-year-old child carrier of the prothrombin 20210A allele. Thromb Haemost 1999; 81:991-2. [PMID: 10404783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
|
25
|
Pagano L, Teofili L, Mele L, Piantelli M, Ranelletti FO, Equitani F, Larocca LM, Leone G. Oral ipriflavone (7-isopropoxy-isoflavone) treatment for elderly patients with resistant acute leukemias. Ann Oncol 1999; 10:124-5. [PMID: 10076734 DOI: 10.1023/a:1008364402623] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
26
|
Rumi C, Rutella S, Lucia BM, Teofili L, De Stefano V, Leone G. APO-1/Fas receptor (CD95) is non-functionally expressed in acute promyelocytic leukemias. Eur J Histochem 1998; 41 Suppl 2:43-4. [PMID: 9859776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023] Open
MESH Headings
- ADP-ribosyl Cyclase
- ADP-ribosyl Cyclase 1
- Antibodies, Monoclonal/pharmacology
- Antigens, CD
- Antigens, Differentiation/metabolism
- Bone Marrow Cells/cytology
- Bone Marrow Cells/drug effects
- Bone Marrow Cells/metabolism
- Cells, Cultured
- Humans
- Interphase
- Leukemia, Promyelocytic, Acute/immunology
- Leukemia, Promyelocytic, Acute/metabolism
- Leukemia, Promyelocytic, Acute/pathology
- Macrophage-1 Antigen/metabolism
- Membrane Glycoproteins
- NAD+ Nucleosidase/metabolism
- Time Factors
- Tretinoin/pharmacology
- fas Receptor/metabolism
Collapse
Affiliation(s)
- C Rumi
- Center for the Flow Cytometric Study of Blood Cells, Catholic University, Rome, Italy
| | | | | | | | | | | |
Collapse
|
27
|
Teofili L, Rutella S, Chiusolo P, La Barbera EO, Rumi C, Ranelletti FO, Maggiano N, Leone G, Larocca LM. Expression of p15INK4B in normal hematopoiesis. Exp Hematol 1998; 26:1133-9. [PMID: 9808052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
The cyclin-dependent kinase inhibitor (CDKI) p15INK4B (p15) induces cell cycle arrest in G0/G1 phase. Several studies report deletion or transcriptional loss of the p15 gene in myeloid and lymphoid hematological malignancies, and a possible role as a tumor suppressor gene has been proposed for this CDKI. In this study we evaluated the expression of p15 by cytofluorometric, immunohistochemical, and reverse transcriptase-polymerase chain reaction (RT-PCR) methods in CD34+ progenitors (both during steady state and after chemotherapy and/or granulocyte-colony stimulating factor [G-CSF] administration) and in cells belonging to different hematopoietic differentiative lineages. We found that p15 is not expressed in normal G0/G1-arrested peripheral blood (PB)- or bone marrow (BM)-CD34+ cells. Moreover, p15 is expressed in G0/G1-blocked CD34+ cells mobilized by chemotherapy and G-CSF but not in CD34+ cells mobilized by G-CSF alone. To clarify the role of p15 in normal hematopoiesis, we used flow cytometry to investigate its expression in normal differentiating BM and PB cells. We found that p15 was expressed in cells belonging to the granulocyte-monocyte lineage and in B and T lymphocytes, whereas erythroid and megakaryocytic cells were p15 negative. These findings, which were confirmed both by immunohistochemical and RT-PCR analysis, definitely establish a linkage between p15 expression and granulocyte-monocyte differentiation.
Collapse
Affiliation(s)
- L Teofili
- Department of Hematology, Università Cattolica del Sacro Cuore, Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
De Stefano V, Chiusolo P, Paciaroni K, Teofili L, La Barbera EO, Casorelli I, Leone G. Hepatic vein thrombosis in a patient with mutant prothrombin 20210A allele. Thromb Haemost 1998; 80:519. [PMID: 9759637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
29
|
De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997; 23:411-8. [PMID: 9387199 DOI: 10.1055/s-2007-996117] [Citation(s) in RCA: 114] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Budd-Chiari syndrome is a severe disease characterized by occlusion of large hepatic veins leading to death if untreated. Using the classical criteria for the diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (IMF), overt PV was the underlying cause in about 10% of the cases and ET or IMF in only a very few. Using spontaneous endogenous erythroid colony (EEC) formation in vitro and/or bone marrow biopsies, a primary myeloproliferative disorder (PMD) was present in 78% of the patients with apparently idiopathic Budd-Chiari syndrome and in about half of the patients with portal, splenic, and/or mesenteric vein thrombosis. The diagnoses in 40 reported cases with hepatic vein thrombosis and spontaneous EEC were overt PV in 25 and latent unclassified PMD in 15 patients. The diagnoses of 40 reported cases with splanchnic vein thrombosis and spontaneous EEC were overt PV in 12, ET in 2, IMF in 2, and latent unclassified PMD with the presence of EEC in 24 patients. Thrombocytosis as a manifestation of myeloproliferative disease was recorded in 34 of 80 (42.5%) patients with spontaneous EEC and Budd-Chiari syndrome or portal vein thrombosis. Thrombocythemia was present in 15 of 41 patients with a proven and in 19 of 39 patients with a latent myeloproliferative disorder. Patients with hepatic vein or splanchnic vein thrombosis associated with a PMD are predominantly females younger than 45. It is concluded that both spontaneous EEC and histopathology from bone marrow biopsy provide specific information as sensitive clues to the diagnosis of all variants of overt and latent myeloproliferative disorders. The association of hepatic and splanchnic vein thrombosis and PMD is not fully understood. Therapeutic options of Budd-Chiari syndrome include anticoagulation with heparin, fibrinolysis followed by oral anticoagulation, and appropriate treatment of the underlying PMD. In case of failure, invasive options include local procedures such as angioplasty or stenting, venous decompression by portal-systemic shunts, or liver transplantation.
Collapse
Affiliation(s)
- V De Stefano
- Department of Hematology, Catholic University Sacred Heart, Rome, Italy
| | | | | | | |
Collapse
|
30
|
Larocca LM, Ranelletti FO, Maggiano N, Rutella S, La Barbera EO, Rumi C, Serra F, Voso MT, Piantelli M, Teofili L, Leone G. Differential sensitivity of leukemic and normal hematopoietic progenitors to the killing effect of hyperthermia and quercetin used in combination: role of heat-shock protein-70. Int J Cancer 1997; 73:75-83. [PMID: 9334813 DOI: 10.1002/(sici)1097-0215(19970926)73:1<75::aid-ijc13>3.0.co;2-4] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Autologous bone-marrow transplantation (ABMT) is widely used in the treatment of acute leukemias where a matched sibling donor is not available for allogeneic transplantation. However, a major problem in ABMT is relapse, and ex vivo purging may be very important in preventing it. We show here that quercetin enhances the growth-inhibitory effect of hyperthermia (HT) in AML (19 cases) and ALL (6 cases) leukemic blasts. Furthermore, the inhibitory effect of this combined treatment resulted in leukemic-cell apoptosis. On the contrary, normal hematopoietic progenitors were neither growth-inhibited nor induced to apoptosis by HT-plus-quercetin treatment. To explain this difference in sensitivity of leukemic and normal hematopoietic progenitors, we analyzed the effect of quercetin on heat-induced expression of heat-shock protein-70 (HSP-70), which has been shown to be important in regulating thermosensitivity. We found that quercetin inhibits heat-induced HSP-70 expression both at protein and at mRNA levels in AML and ALL blasts. In normal CD34+ progenitors, the combined treatment with HT and quercetin did not reduce HSP-70 expression and did not induce cell apoptosis. Considering the difference in heat sensitivity of normal CD34+ and leukemic progenitors in the presence of quercetin, the combined use of HT and quercetin could constitute a purging protocol for ABMT.
Collapse
Affiliation(s)
- L M Larocca
- Istituto di Anatomia Patologica, Università Cattolica del Sacro Cuore, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Rutella S, Rumi C, Testa U, Sica S, Teofili L, Martucci R, Peschle C, Leone G. Inhibition of lymphocyte blastogenic response in healthy donors treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF): possible role of lactoferrin and interleukin-1 receptor antagonist. Bone Marrow Transplant 1997; 20:355-64. [PMID: 9339749 DOI: 10.1038/sj.bmt.1700899] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The effects of rhG-CSF on lymphocyte blastogenesis were evaluated in six healthy donors, submitted to progenitor cell mobilization for allogeneic transplantation. Neutrophil, monocyte and lymphocyte count increased 6.7-fold, 5.3-fold and 2.0-fold on day +4 of rhG-CSF as compared with baseline. The DNA stimulation index (DNA SI) of 72 h phytohemagglutinin (PHA)-treated cultures decreased from 20% (15-35.5) prior to rhG-CSF to 6.7% (1.5-11.9; P = 0.0026), 8% (4-12; P = 0.0091) and 15% (9-22; P = 0.0091) on days +2, +4 and +6; similarly, reactivity to concanavalin A decreased from 18% (12-20) to 1.8% (0.5-7; P < 0.01), 3% (2-8; P < 0.01) and 5% (2-11; P = 0.009). No changes of lymphocyte response to pokeweed mitogen were observed. DNA SI of PHA-treated cultures inversely correlated with neutrophil and monocyte count. IL-1 receptor antagonist (IL-1ra) and lactoferrin (Lf) plasma levels sharply increased and correlated with neutrophil and monocyte count. IL-10 increased five-fold on day +2, returned to pretreatment values thereafter and did not show any correlation with DNA SI, suggesting that it was not responsible for the observed phenomena. Interestingly, DNA SI of PHA-treated cultures inversely correlated with IL-1ra and Lf levels. CD3+ and CD19+ lymphocyte activation status, ie CD23, CD25, CD30 and HLA-DR coexpression, was not affected by rhG-CSF administration. Pharmacological doses of rhG-CSF in healthy donors inhibit lymphocyte blastogenesis via an increased production and/or release of immunoregulatory soluble mediators, ie IL-1ra and Lf, by primed neutrophils and monocytes.
Collapse
Affiliation(s)
- S Rutella
- Center for the Flow Cytometric Study of Blood Cells and Department of Hematology, Catholic University, Rome, Italy
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Rumi C, Rutella S, Teofili L, Etuk B, Ortu La Barbera E, Micciulli G, Voso MT, Leone G. RhG-CSF-mobilized CD34+ peripheral blood progenitors are myeloperoxidase-negative and noncycling irrespective of CD33 or CD13 coexpression. Exp Hematol 1997; 25:246-51. [PMID: 9091301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Cycling status, myeloperoxidase expression, informative surface markers, and proliferative potential of peripheral blood hemopoietic progenitors (PBHP) were evaluated by flow cytometry in 10 patients affected by resistant lymphoma, and submitted to stem cell mobilization with combination chemotherapy (MiCMA) followed by recombinant human granulocyte colony-stimulating factor (rhG-CSF, 5 micrograms/kg/day). CD34+ PBHP coexpressed myeloid-associated and activation antigens, i.e., CD33 (96%, range 85-99), CD13 (99.5%, range 99.4-99.8), HLA-DR (99%, range 96.5-99.8), and CD38 (98%, range 90-100), lacked intracytoplasmic myeloperoxidase (MPO, < 3%), and resided in the Gzero/G1 phase of the cell cycle (96.5%, range 81-99.5, compared with 70%, range 49-78 bone marrow HP; p = 0.0007), independently of surface membrane phenotype; S-phase percentages of sorted CD34+ CD33(+)/-, CD34+CD38(+)/-, CD34+HLA-DR(+)/-, CD34+CD45RA(+)/-, CD34+CD45RO(+)/-, and CD34+CD41a(+)/- subpopulations were always negligible. In colony assays, 5-week-old long-term cultures seeded with CD34+CD33- cells yielded as many colonies as did CD34+CD33+ cells. In conclusion, rhG-CSF-mobilized CD34+ PBHPs contain noncycling, highly immature progenitors in which the expression of myeloid-associated antigens, i.e., CD33 or CD13, might not be indicative of myeloid commitment.
Collapse
Affiliation(s)
- C Rumi
- Center for the Flow Cytometric Study of Blood Cells, Catholic University, Rome, Italy
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
The bioflavonoid quercetin (3, 3', 4', 5-7-pentahydroxyflavone) inhibits in a dose-dependent manner the in vitro growth of acute leukemias and enhances the anti-proliferative activity of cytosine arabinoside. Quercetin exerts a blocking action of cell transition from the G0/G1 to the S phase of the cell cycle. Acute myeloid leukemias (AML)-M3,-M4 and -M5, and acute lymphoid leukemias (ALL) were more sensitive to quercetin than AML-M1 and -M2 subtypes. The sensitivity of leukemic progenitors to the growth inhibitory effect of quercetin significantly correlated with their clonogenic efficiency. We postulate that quercetin exerts its growth inhibitory action by interaction with type II estrogen binding sites and subsequent induction of Transforming Growth Factor-beta 1 expression and secretion. Finally quercetin is synergistic with hyperthermia in inducing apoptosis of leukemic cells sparing normal stem cell progenitors. Taken together these results stress the potential role of quercetin in the treatment of acute leukemias and its in vitro use in purging procedures for autologous bone marrow transplantation.
Collapse
Affiliation(s)
- L M Larocca
- Istituti di Anatomia Patologica, Università Cattolica del Sacro Cuore., Roma, Italy
| | | | | | | | | | | |
Collapse
|
34
|
Teofili L, Rutella S, Pierelli L, Ortu la Barbera E, Di Mario A, Menichella G, Rumi C, Leone G. Separation of chemotherapy plus G-CSF-mobilized peripheral blood mononuclear cells by counterflow centrifugal elutriation: in vitro characterization of two different CD34+ cell populations. Bone Marrow Transplant 1996; 18:421-5. [PMID: 8864456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Counterflow centrifugal elutriation (CCE) has been extensively employed in T cell depletion of bone marrow cells for allografting. Nevertheless very little is known about CCE properties of mobilized hematopoietic progenitors. In this study five leukapheresis products collected after chemotherapy and G-CSF from patients with non-Hodgkin's lymphoma were elutriated. Two mononuclear cell fractions were obtained containing smaller and less dense cells (lymphocyte fraction) and larger and denser cells (monocyte fraction), respectively. The presence of immature CD34+ progenitor cells, not co-expressing CD33, CD38 and HLA-DR antigens, was demonstrated in both cell fractions. CD34+ cells were isolated from each fraction and grown in various culture conditions (CFU-GM and BFU-E assay, blast cell colony assay, cytokine supplemented liquid culture). CD34+ cells isolated from the monocyte fraction showed a longer lasting expansion in liquid culture and a higher number of blast cell colonies than CD34+ cells selected from the lymphocyte fraction. Moreover a significant reduction of T cell number was obtained in the monocyte fraction. These data suggest that chemotherapy plus G-CSF-mobilized progenitor cells show a characteristic behavior when subjected to CCE, allowing an efficient T cell depletion without losing more immature progenitors.
Collapse
Affiliation(s)
- L Teofili
- Istituto di Semeiotica Medica, Università Cattolica del Sacro Cuore, Roma, Italy
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Rutella S, Rumi C, Teofili L, Etuk B, Ortu La Barbera E, Leone G. RhG-CSF-mobilized peripheral blood haemopoietic progenitors reside in G0/G1 phase of cell cycle independently of the expression of myeloid antigens. Br J Haematol 1996; 93:737-8. [PMID: 8652404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
|
36
|
|
37
|
Larocca LM, Piantelli M, Teofili L, Leone G, Ranelletti FO. Concentration and effect of quercetin. Exp Hematol 1996; 24:494-6. [PMID: 8608798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
38
|
De Stefano V, Teofili L, Sica S, Mastrangelo S, Di Mario A, Rutella S, Salutari P, Rumi C, d'Onofrio G, Leone G. Effect of all-trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia. Blood 1995; 86:3535-41. [PMID: 7579461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
The mechanisms underlying acute promyelocytic leukemia (APL) coagulopathy and its reversal by administration of all-trans retinoic acid (ATRA) have been investigated. Bone marrow promyelocytic blasts from nine patients with APL were cultured with or without ATRA 1 mumol/L. Cultured blasts (days 0, 3, 6, and 9) were washed, resuspended in phosphate buffer, lysed by freezing and thawing, and then assayed for procoagulant activity (PCA), elastase activity, tissue factor (TF) antigen, tissue-type plasminogen activator (t-PA) antigen and urokinase-type plasminogen activator (u-PA) antigen. PCA was determined by a recalcification assay. Elastase was measured by an amidolytic assay (S-2484). TF, t-PA, and u-PA antigens were measured by an enzyme-linked immunosorbent assay (ELISA). Malignant promyelocytes isolated from the patients had increased levels of PCA and TF as compared with the control polymorphonucleates, and low levels of elastase, t-PA, and u-PA; the patient blast PCA level was significantly related to the degree of hypofibrinogenemia. In this system, blast PCA depended on the tissue factor and was significantly correlated to the TF antigen values. In the cultures without ATRA, PCA, TF, and u-PA progressively increased, whereas elastase and t-PA levels remained essentially unchanged. In the presence of ATRA, all parameters (except u-PA) decreased during the culture time. Thus, a major role of the promyelocytic blast cell PCA in the pathogenesis of M3-related coagulopathy is suggested; the ATRA effect on coagulopathy seems mainly mediated by a downregulation of the PCA.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aprotinin/pharmacology
- Blood Coagulation/drug effects
- Cell Differentiation/drug effects
- Cysteine Endopeptidases/biosynthesis
- Cysteine Endopeptidases/genetics
- Female
- Fibrinolysis/drug effects
- Gene Expression Regulation, Leukemic/drug effects
- Hemorrhagic Disorders/etiology
- Hemorrhagic Disorders/physiopathology
- Humans
- Leukemia, Promyelocytic, Acute/blood
- Leukemia, Promyelocytic, Acute/complications
- Leukemia, Promyelocytic, Acute/genetics
- Leukemia, Promyelocytic, Acute/pathology
- Male
- Middle Aged
- Neoplasm Proteins/biosynthesis
- Neoplasm Proteins/genetics
- Neoplastic Stem Cells/drug effects
- Neoplastic Stem Cells/metabolism
- Pancreatic Elastase/biosynthesis
- Pancreatic Elastase/genetics
- Thromboplastin/biosynthesis
- Thromboplastin/genetics
- Tissue Plasminogen Activator/biosynthesis
- Tissue Plasminogen Activator/genetics
- Tretinoin/pharmacology
- Tumor Cells, Cultured
- Urokinase-Type Plasminogen Activator/biosynthesis
- Urokinase-Type Plasminogen Activator/genetics
Collapse
Affiliation(s)
- V De Stefano
- Istituto di Semeiotica Medica, Università Cattolica, Rome, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Larocca LM, Teofili L, Sica S, Piantelli M, Maggiano N, Leone G, Ranelletti FO. Quercetin inhibits the growth of leukemic progenitors and induces the expression of transforming growth factor-beta 1 in these cells. Blood 1995; 85:3654-61. [PMID: 7780149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
We previously showed that quercetin (3,3',4',5,7 pentahydroxyflavone) inhibits in a dose-dependent manner the growth of acute leukemias and is able to enhance the antiproliferative activity of cytosine arabinoside. We show here that quercetin inhibits the clonogenic activity of 20 of 22 acute leukemias (AL; 4 M1-AML, 3 M2-AML, 2 M3-AML, 3 M4-AML, 3 M5-AML, and 7 ALL). In the present report, we show that the induction of transforming growth factor-beta 1 (TGF-beta 1) in leukemic blasts is one of the growth-inhibitory mechanisms of quercetin in these cells. This observation was supported by the following data. (1) Quercetin-sensitive leukemic blasts, when treated with quercetin, secrete large amounts of TGF-beta 1 in the medium and show positivity for TGF-beta 1-immunoreactive material in the cytoplasm. (2) At a concentration of 8 mumol/L, antisense TGF-beta 1 oligonucleotides prevent the growth-inhibitory action of quercetin. (3) Anti-TGF-beta 1 neutralizing monoclonal antibodies can prevent almost completely the growth-inhibitory activity of quercetin. The analysis of quercetin-resistant cases confirmed as well the central role of TGF-beta 1 in the growth-inhibitory activity of quercetin. In conclusion, quercetin can act as a cytostatic agent for leukemic cells by modulating the production of TGF-beta 1.
Collapse
Affiliation(s)
- L M Larocca
- Istituti di Anatomia Patologica, Università Cattolica del Sacro Cuore, Roma, Italy
| | | | | | | | | | | | | |
Collapse
|
40
|
Teofili L, Iovino MS, Sica S, Pierelli L, Menichella G, De Stefano V, Rumi C, Leone G. Characterization of peripheral blood CD34+ progenitor cells mobilized with chemotherapy and granulocyte colony-stimulating factor. Exp Hematol 1994; 22:990-5. [PMID: 7522187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Peripheral blood (PB) mononuclear cells mobilized with chemotherapy and granulocyte colony-stimulating factor (G-CSF) were enriched in CD34+ cells; aliquots were seeded in long-term cultures (LTC) on bone marrow (BM)-derived stromal layers and in liquid cultures containing various growth factors. The final recovery of PB CD34+ cells was similar to normal BM controls, and no difference was found in the expression of CD33 and CD13 antigens; a lower number of CD34+/HLA-DR- cells was found in PB with respect to BM samples (p < 0.001). PB cells sustained hematopoiesis in LTC at least as long as BM cells. At week 3 and 4, PB total mononuclear cell (MC) and CD34(+)-selected cell cultures showed a higher nonadherent cell recovery compared to the respective BM controls (p = 0.05 and p < 0.01). The liquid culture of PB CD34+ cells in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and stem cell factor (SCF) resulted in a marked and long-lasting increase of colony-forming units-granulocyte/macrophage (CFU-GM). Taken together, our data suggest that chemotherapy and G-CSF-primed cells contain a considerable number of both committed and early precursors, accounting for the rapid hematopoietic recovery observed after their reinfusion following myeloablative chemotherapy.
Collapse
Affiliation(s)
- L Teofili
- Department of Hematology, Catholic University of Sacred Heart, Rome, Italy
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Pierelli L, Menichella G, Scambia G, Teofili L, Iovino S, Serafini R, Benedetti Panici P, Salerno G, Rumi C, Zini G. In vitro and in vivo effects of recombinant human erythropoietin plus recombinant human G-CSF on human haemopoietic progenitor cells. Bone Marrow Transplant 1994; 14:23-30. [PMID: 7524905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
We tested in vitro the effect of recombinant human erythropoietin (rhEPO) plus recombinant human G-CSF (rhG-CSF) on purified human CD34+ haemopoietic progenitors (HP) and in vivo in patients who had undergone anti-cancer chemotherapy for advanced ovarian cancer. In this preliminary experience we found that, in vitro, rhEPO potentiates the effect of rhG-CSF on HP growth and differentiation toward the granulocyte-macrophage lineage. rhEPO plus rhG-CSF produced in vitro a proliferative stimulus of HP which represents 26% of the maximum stimulation obtained using IL-1, IL-3, IL-6, G-CSF, GM-CSF and stem cell factor in combination. In the patients treated with rhEPO plus rhG-CSF after chemotherapy, we observed a favourable trend for platelet and neutrophil recoveries compared with a control group treated with rhG-CSF alone and a significantly higher haematocrit nadir was observed in the rhEPO plus rhG-CSF series. In the patients treated with rhEPO plus rhG-CSF we observed a significant increase of circulating colony-forming unit granulocyte-macrophage (CFU-GM) and burst forming unit-erythroid (BFU-e) compared with the rhG-CSF series. Our results, in vitro and in vivo, encourage the in vivo use of rhEPO plus rhG-CSF to improve blood cell recoveries of patients who have undergone conventional or high-dose chemotherapy. Moreover, rhEPO plus rhG-CSF was demonstrated to be a good HP mobilising treatment for blood stem cell collection after chemotherapy.
Collapse
Affiliation(s)
- L Pierelli
- Centro Richerche per la Manipolazione dei Costituenti Ematici, Catholic University, Rome, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Sica S, Di Mario A, Salutari P, Etuk B, Jovino MS, Pierelli L, Marra R, Teofili L, Menichella G, D'Onofrio G. Sequential peripheral blood progenitor cell transplantation after mobilization with salvage chemotherapy and G-CSF in patients with resistant lymphoma. Am J Hematol 1994; 46:18-23. [PMID: 7514355 DOI: 10.1002/ajh.2830460104] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
We enrolled 18 patients affected by refractory or relapsed lymphoma (HD, NHL) in a two-step protocol that included salvage chemotherapy with mitoxantrone, carboplatinum, methylprednisolone, and cytosine arabinoside (MiCMA) plus G-CSF (5 micrograms/kg/day), peripheral blood progenitor cell (PBPC) collection, and subsequent transplantation after BUCY2 regimen. After MiCMA chemotherapy, four patients (22%) achieved complete response, eight patients (44%) obtained a partial response, and six showed progression of disease (PD). Fourteen out of 18 patients (78%) were considered eligible for PBPC transplantation. Three patients with complete response refused PBPCT; they are currently in continuous complete remission (CCR) at 15, 13, and 15 months, respectively. One patient has been recently transplanted but is too early to be evaluated. Ten patients so far completed the study, eight of whom are currently alive in CR, with a median follow-up of 7.5 months (range 2-13). Hematologic reconstitution was very rapid with a median time to achieve WBC > 1 x 10(9)/L, PMN > 0.5 x 10(9)/L, platelets > 50 x 10(9)/L and > 100 x 10(9)/L of 13 (range 9-15), 12 (range 9-14), 10 (range 0-22), and 14 (range 5-49) days, respectively. Our protocol is highly effective as a salvage treatment, while permitting PBPC collection after G-CSF administration. Hemopoietic reconstitution after transplantation of PBPCs collected with this procedure is complete, rapid, and sustained.
Collapse
Affiliation(s)
- S Sica
- Istituto di Semeiotica Medica, Università Cattolica Sacro Cuore, Rome, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Teofili L, Iovino MS, Di Mario A, Ortu La Barbera E, Pierelli L, Bussa S, Rumi C, Menichella G, Leone G. In vitro expansion of CD34+ cells mobilized with chemotherapy and G-CSF. Int J Artif Organs 1993; 16 Suppl 5:89-95. [PMID: 7516922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Hemopoietic CD34+ progenitors were isolated by immunomagnetic method from normal bone marrow (BM) or from peripheral blood (PB) of patients with non-Hodgkin's lymphoma treated with chemotherapy and granulocyte colony-stimulating factor (GCSF). Aliquots were seeded in long-term cultures (LTC) on bone marrow-derived stromal layers; non-adherent and adherent clonogenic content of the cultures was assayed weekly. The final recovery and the clonogenic efficiency of the CD34+ cells were slightly higher in PB samples than in BM controls. In long term cultures PB cells sustained hemopoiesis as much as BM cells; at week 3 and 4 PB total mononuclear cells and CD34+ cells showed a non-adherent cell recovery higher than the respective BM controls. Furthermore, PB CD34+ cells were expanded in liquid culture in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF alone or combined with interleukin 3 (IL3), stem cell factor (SCF), interleukin 1 (IL1), interleukin 6 (IL6). The combination of GM-CSF, IL3, SCF, IL1 and IL6 produced the maximum increase of both mononuclear cells (30-fold) and granulocyte-macrophage colony forming units (CFU-GM) (4.6-fold) after 7 days of cultures; yet after 14 days a strong decrease of the CFU-GM occurred. These data suggest that G-CSF following chemotherapy mobilizes both early and committed hemopoietic progenitors.
Collapse
Affiliation(s)
- L Teofili
- Department of Hematology, Sacro Cuore University, Roma, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
De Luca A, Teofili L, Antinori A, Iovino MS, Mencarini P, Visconti E, Tamburrini E, Leone G, Ortona L. Haemopoietic CD34+ progenitor cells are not infected by HIV-1 in vivo but show impaired clonogenesis. Br J Haematol 1993; 85:20-4. [PMID: 7504507 DOI: 10.1111/j.1365-2141.1993.tb08640.x] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
We evaluated the role of CD34+ bone marrow progenitor cells in vivo, in the pathogenesis of AIDS-related haematological abnormalities. The clonogenic activity of CD34+ cells from seven patients with HIV-1 infection, without bone marrow involving opportunistic infections or neoplasms, was assessed in semisolid cultures. The number of CFU-GM was significantly reduced as compared to the controls (P = 0.017), independently from myelotoxic therapy, while the number of BFU-E was not. The presence of retroviral sequences in CFU-GM colonies from four patients and in the total population of CD34+ cells from six patients with advanced stage HIV infection was investigated using the polymerase chain reaction. The presence of HIV-1 sequences was also searched for in a purified suspension of CD34+ cells after 3 weeks liquid culture. All these cells were always HIV-1 negative, while viral sequences were always detected in bone marrow mononuclear cells from these and other patients. The number of HIV-1 DNA copies decreased with increasing enrichment. At most 1:10,000 CD34+ cells are infected in vivo. Other mechanisms than direct viral infection of progenitor cells must account for the defective haemopoiesis in HIV-1 infected patients.
Collapse
Affiliation(s)
- A De Luca
- Istituti di Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Pierelli L, Teofili L, Menichella G, Rumi C, Paoloni A, Iovino S, Puggioni PL, Leone G, Bizzi B. Further investigations on the expression of HLA-DR, CD33 and CD13 surface antigens in purified bone marrow and peripheral blood CD34+ haematopoietic progenitor cells. Br J Haematol 1993; 84:24-30. [PMID: 7687858 DOI: 10.1111/j.1365-2141.1993.tb03021.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
We evaluated the HLA-DR, CD33 and CD13 antigen expression on CD34+ haematopoietic progenitor cells (HPC) isolated from the bone marrow (BM) and peripheral blood (PB) of normal donors. The majority of both BM and PB CD34+ HPC expressed CD13 and HLA-DR. The coexpression of CD34 and CD33 was found in a minor CD34+ subset. After 7 d of culture in the presence of interleukin-3 and granulocyte-macrophage colony-stimulating factor, CD33 expression was detected in about 50% of HPC. At this point CD34 antigen expression was lost and CD13 and HLA-DR expression was partially lost. After 14 d of culture, the majority of HPC were CD33+. HPC maintained the capacity to generate colony forming unit granulocyte-macrophage but they lost the capacity to generate burst forming unit-erythroid. A correlation was found between the percentage of CD34+/HLA-DR+ cells and the total number of colony forming cells in unfractionated samples from BM and PB of patients with malignancies. These studies demonstrate that, in normal conditions, only a minor subset of CD34+ cells coexpress CD33 antigen either in BM or in PB and CD33 antigen is a lineage marker which is coexpressed with HLA-DR and CD13 on a progenitor committed to the granulocytic-macrophagic lineage.
Collapse
Affiliation(s)
- L Pierelli
- Servizio di Ematologia ed Emotransfusione, Catholic University, Rome
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Teofili L, Iovino M, Di Mario A, La Barbera EO, Pierelli L, Bussa S, Rumi C, Menichella G, Leone G. In Vitro Expansion of CD34+ Cells Mobilized with Chemotherapy and G-CSF. Int J Artif Organs 1993. [DOI: 10.1177/039139889301605s17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Hemopoietic CD34+ progenitors were isolated by immunomagnetic method from normal bone marrow (BM) or from peripheral blood (PB) of patients with non-Hodgkin's lymphoma treated with chemotherapy and granulocyte colony-stimulating factor (GCSF). Aliquots were seeded in longterm cultures (LTC) on bone marrow-derived stromal layers; non-adherent and adherent clonogenic content of the cultures was assayed weekly. The final recovery and the clonogenic efficiency of the CD34+ cells were sligthly higher in PB samples than in BM controls. In long term cultures PB cells sustained hemopoiesis as much as BM cells; at week 3 and 4 PB total mononuclear cells and CD34+ cells showed a non-adherent cell recovery higher than the respective BM controls. Furthermore, PB CD34+ cells were expanded in liquid culture in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF alone or combined with interleukin 3 (IL3), stem cell factor (SCF), interleukin 1 (IL 1), interleukin 6 (IL6). The combination of GM-CSF, IL3, SCF, IL 1 and IL6 produced the maximum increase of both mononuclear cells (30-fold) and granulocyte-macrophage colony forming units (CFU-GM) (4.6-fold) after 7 days of cultures; yet after 14 days a strong decrease of the CFU-GM occurred. These data suggest that G-CSF following chemotherapy mobilizes both early and committed hemopoietic progenitors.
Collapse
Affiliation(s)
- L. Teofili
- Department of Hematology, Internal Medicine Institute, “Sacro Cuore” University, Roma - Italy
| | - M.S. Iovino
- Department of Hematology, Internal Medicine Institute, “Sacro Cuore” University, Roma - Italy
| | - A. Di Mario
- Department of Hematology, Internal Medicine Institute, “Sacro Cuore” University, Roma - Italy
| | - E. Ortu La Barbera
- Department of Hematology, Internal Medicine Institute, “Sacro Cuore” University, Roma - Italy
| | - L. Pierelli
- Department of Hematology, Internal Medicine Institute, “Sacro Cuore” University, Roma - Italy
| | - S. Bussa
- Department of Hematology, Internal Medicine Institute, “Sacro Cuore” University, Roma - Italy
| | - C. Rumi
- Department of Hematology, Internal Medicine Institute, “Sacro Cuore” University, Roma - Italy
| | - G. Menichella
- Department of Hematology, Internal Medicine Institute, “Sacro Cuore” University, Roma - Italy
| | - G. Leone
- Department of Hematology, Internal Medicine Institute, “Sacro Cuore” University, Roma - Italy
| |
Collapse
|
47
|
Teofili L, De Stefano V, Iovino M, Mastrangelo S, Sica S, Ortu E, Bizzi B, Leone G. Effect of all-transretinoic acid on procoagulant activity of promyelocytic blast cells in culture. Thromb Res 1993. [DOI: 10.1016/0049-3848(93)90357-t] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
48
|
Teofili L, De Stefano V, Iovino MS, Bizzi B, Leone G. An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. Cancer 1992; 70:1647-8; author reply 1648-9. [PMID: 1516018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
49
|
Leone G, Sica S, De Stefano V, Teofili L, Larocca LM, D'Onofrio G, Zollino M. Acute onset of juvenile myelodysplastic syndrome mimicking thrombotic thrombocytopenic purpura and rapidly evolving in overt myeloid leukemia. Am J Hematol 1992; 41:64-5. [PMID: 1503103 DOI: 10.1002/ajh.2830410114] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
50
|
Leone G, La Rocca LM, Teofili L, De Candia E, Landolfi R, Sica S, Zini G, Zollino M, Tabilio A. Lymph node blast crisis in chronic myeloid leukemia mimicking T-immunoblastic lymphoma. Haematologica 1992; 77:311-4. [PMID: 1427440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Chronic myeloid leukemia arises from a somatic mutation in a pluripotent stem cell. It generally terminates with a blastic crisis (BC). One third of BC are lymphoid, and most have a pre-B phenotype. Few cases of T-lymphoid BC have been reported. Here we describe a lymph node blast crisis mimicking T-immunoblastic lymphoma. METHODS Bone marrow and lymph nodes were histologically examined by standard methods and by an immunoperoxidase technique. Cytogenetic studies were also performed on lymph node and blood cells. Analysis of T-cell receptor genes and BCR rearrangements were performed on DNA extracted from both frozen bone marrow and lymph-node cells. RESULTS Lymph-node histology showed an infiltration by large lymphoid blasts, consistent with a diagnosis of immunoblastic lymphoma. Blast cells were CD2, CD7, TDT positive, and negative for myeloid and mature lymphoid antigens. The Ph1 chromosome was found in both bone marrow and lymph-node cells. BCR rearrangement was found in the DNA from both bone marrow and lymph-node cells. TCR genes were not rearranged. DISCUSSION The present study provides strong evidence that the lymph-node blast crisis of CML can assume the morphological appearance of immunoblastic lymphoma and may retain the immunological phenotype and genetic features of early T cells with BCR rearrangements.
Collapse
MESH Headings
- Antigens, Neoplasm/analysis
- Biomarkers, Tumor/analysis
- Blast Crisis/diagnosis
- Blast Crisis/pathology
- Bone Marrow/pathology
- Fusion Proteins, bcr-abl/genetics
- Gene Rearrangement, T-Lymphocyte
- Humans
- Immunophenotyping
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Lymph Nodes/pathology
- Lymphoma, Large-Cell, Immunoblastic/diagnosis
- Lymphoma, T-Cell/diagnosis
- Male
- Middle Aged
Collapse
Affiliation(s)
- G Leone
- Istituti di Semeiotica Medica, Università Cattolica del S. Cuore, Roma, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|